Motley Fool  Dec 11  Comment 
A robust clinical-stage pipeline helped investors forget about Arena's ill-fated weight-loss drug.
Motley Fool  Nov 7  Comment 
You could say that Arena "posterized" Wall Street in October and was rewarded for it.
Motley Fool  Oct 9  Comment 
Preclinical data strengthened the case for Arena's lead candidate.
Benzinga  Sep 12  Comment 
On CNBC's "Mad Money Lightning Round", Jim Cramer said Allergan plc (NYSE: AGN) is an inexpensive stock and he would buy it. He explained that the stock is struggling at the moment, because the company has a drug that might come off...


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki